Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine . (23rd March 2022)

• Record Type: Journal Article
• Authors: Maron, Jenny S; Conroy, Michelle; Naranbai, Vivek; Samarakoon, Upeka; Motazedi, Tina; Farmer, Jocelyn R; Freeman, Esther; Banerji, Aleena; Bartsch, Yannic C; Gregory, David J; Poznansky, Mark C; Alter, Galit; Blumenthal, Kimberly G
• Is Part Of: Journal of infectious diseases. Volume 226:Number 7(2022)
• Page Start: 1231
• Page End: 1236
• Publication Date: 2022-03-23
• Subjects: systems serology -- SARS-CoV-2 -- anaphylaxis -- hypersensitivity -- Pfizer -- Moderna -- messenger RNA -- COVID-19 -- vaccination -- humoral immunity; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiac107
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Allergic symptoms after messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines occur in up to 2% of recipients. Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower immunoglobulin G1 (IgG1 ) to multiple antigenic targets in severe acute respiratory syndrome coronavirus 2 spike following vaccination, with significantly lower IgG1 to full-length spike ( P = .04). Individuals with immediate allergic reactions to mRNA COVID-19 vaccines bound Fcγ receptors similarly to nonallergic controls. Although there was a trend toward an overall reduction in opsonophagocytic function in individuals with immediate allergic reactions compared to nonallergic controls, allergic patients produced functional antibodies exhibiting a high ratio of opsonophagocytic function to IgG1 titer. Abstract : Compared to nonallergic controls (n = 18), individuals with immediate allergic reactions to mRNA COVID-19 vaccines (n = 8) mounted lower IgG1 to multiple antigenic targets in SARS-CoV-2 spike following vaccination, with significantly lower IgG1 to full-length spike ( P = .04).